Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Orchestra BioMed Holdings, Inc.HSAQ · Entity 434 | Director | August 03, 2020 | August 10, 2020 |
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | Director · CHIEF EXECUTIVE OFFICER | January 31, 2023 | February 02, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Orchestra BioMed Holdings, Inc.
Report date August 03, 2020 · Filed August 10, 2020 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 22,261 |
Reported balance
Holding disclosure · report date 2020-08-03 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 22,261 |
PTC THERAPEUTICS, INC.
Report date January 31, 2023 · Filed February 02, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 166,962 |
Reported balance
After 2023-01-31 transaction · row 1
1 source rowRow 1 · 2023-01-31 · Sale · Disposed 2,320 · Balance 166,962 F1: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 8,250 RSUs from a January 29, 2020 grant of 33,000 RSUs. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 54,903 |
Reported balance
After 2023-01-31 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-01-31 · Sale · Disposed 301 · Balance 54,903 F2: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 1,214 RSUs from a January 29, 2020 grant of 4,855 RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 8,250 RSUs from a January 29, 2020 grant of 33,000 RSUs.
F2: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 1,214 RSUs from a January 29, 2020 grant of 4,855 RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 31, 2023 Filed Feb 2, 2023 21:22 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 301 | $45.63 | $13,734.03 |
DisclosureSEC source: 0001415889-23-001803 · form4-02022023_090218.xml · nonDerivative · entry 2 Peltz Stuart Walter · CIK 0001578962 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 54,903 F2 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 1,214 RSUs from a January 29, 2020 grant of 4,855 RSUs. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 21:22 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,320 | $45.63 | $105,856.96 |
DisclosureSEC source: 0001415889-23-001803 · form4-02022023_090218.xml · nonDerivative · entry 1 Peltz Stuart Walter · CIK 0001578962 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,962 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 8,250 RSUs from a January 29, 2020 grant of 33,000 RSUs. Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 21:24 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 284 | $47.45 | $13,476.17 |
DisclosureSEC source: 0001415889-23-001461 · form4-01262023_090102.xml · nonDerivative · entry 1 Peltz Stuart Walter · CIK 0001578962 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 55,204 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 1,155 shares of restricted stock from a January 22, 2019 grant of 4,620 shares of restricted stock. Read SEC document |
| January 11, 2023 Filed Jan 12, 2023 21:34 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 492 | $44.36 | $21,824.92 |
DisclosureSEC source: 0001415889-23-000877 · form4-01122023_090118.xml · nonDerivative · entry 4 Peltz Stuart Walter · CIK 0001578962 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 55,488 F2 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 4,200 RSUs from a January 7, 2022 grant of 16,800 RSUs. Read SEC document |
| January 11, 2023 Filed Jan 12, 2023 21:34 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,189 | $44.36 | $52,743.56 |
DisclosureSEC source: 0001415889-23-000877 · form4-01122023_090118.xml · nonDerivative · entry 3 Peltz Stuart Walter · CIK 0001578962 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,282 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 11,000RSUs from a January 7, 2022 grant of 44,000 RSUs. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 21:34 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 571 | $42.93 | $24,514.69 |
DisclosureSEC source: 0001415889-23-000877 · form4-01122023_090118.xml · nonDerivative · entry 2 Peltz Stuart Walter · CIK 0001578962 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 55,980 F2 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 4,200 RSUs from a January 7, 2022 grant of 16,800 RSUs. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 21:34 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,228 | $42.93 | $52,721.60 |
DisclosureSEC source: 0001415889-23-000877 · form4-01122023_090118.xml · nonDerivative · entry 1 Peltz Stuart Walter · CIK 0001578962 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,471 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 11,000RSUs from a January 7, 2022 grant of 44,000 RSUs. Read SEC document |
| January 09, 2023 Filed Jan 11, 2023 23:11 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 279 | $41.66 | $11,622.08 |
DisclosureSEC source: 0001415889-23-000834 · form4-01112023_110123.xml · nonDerivative · entry 2 Peltz Stuart Walter · CIK 0001578962 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 56,551 F2 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 990 RSUs from a January 6, 2021 grant of 3,960 RSUs. Read SEC document |
| January 09, 2023 Filed Jan 11, 2023 23:11 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,786 | $41.66 | $74,397.97 |
DisclosureSEC source: 0001415889-23-000834 · form4-01112023_110123.xml · nonDerivative · entry 1 Peltz Stuart Walter · CIK 0001578962 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,699 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 6,900 RSUs from a January 6, 2021 grant of 27,600 RSUs. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 21:51 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $39.42 | $0.00 |
DisclosureSEC source: 0001415889-23-000688 · form4-01092023_090142.xml · derivative · entry 4 Peltz Stuart Walter · CIK 0001578962 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2033-01-04 F3 · derivative.exercise_date: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 21:51 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 132,500 | $0.00 Strike: $39.42 | $0.00 |
DisclosureSEC source: 0001415889-23-000688 · form4-01092023_090142.xml · derivative · entry 3 Peltz Stuart Walter · CIK 0001578962 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,500 Underlying: Common Stock · 132,500 shares Expires 2033-01-04 F3 · derivative.exercise_date: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 21:51 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-000688 · form4-01092023_090142.xml · nonDerivative · entry 2 Peltz Stuart Walter · CIK 0001578962 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 56,830 F1 · shares: Restricted stock units granted on January 5, 2023 that vest in four equal installments over four years, commencing on January 5, 2024. F2 · balance_after: Includes 293 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending June 30, 2022 and 298 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending December 31, 2022. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 21:51 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 53,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-000688 · form4-01092023_090142.xml · nonDerivative · entry 1 Peltz Stuart Walter · CIK 0001578962 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,485 F1 · shares: Restricted stock units granted on January 5, 2023 that vest in four equal installments over four years, commencing on January 5, 2024. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:03 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 407 | $26.83 | $10,919.00 |
DisclosureSEC source: 0001415889-22-006356 · form4-06092022_010616.xml · nonDerivative · entry 1 Peltz Stuart Walter · CIK 0001578962 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 38,239 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 1,560 RSUs from a June 11, 2021 grant of 6,240 RSUs. Read SEC document |
| April 14, 2022 Filed Apr 15, 2022 20:04 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 82 | $45.28 | $3,712.88 |
DisclosureSEC source: 0001415889-22-004083 · form4-04152022_010446.xml · nonDerivative · entry 1 Peltz Stuart Walter · CIK 0001578962 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 38,646 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 350 RSUs from an April 13, 2021 grant of 1,400 RSUs. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:58 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 282 | $40.00 | $11,280.56 |
DisclosureSEC source: 0001179110-22-000840 · edgar.xml · nonDerivative · entry 2 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 38,728 F2 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 1,214 RSUs from a January 29, 2020 grant of 4,855 RSUs. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:58 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,961 | $40.00 | $78,443.92 |
DisclosureSEC source: 0001179110-22-000840 · edgar.xml · nonDerivative · entry 1 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,485 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 8,250 RSUs from a January 29, 2020 grant of 33,000 RSUs. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 21:02 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 330 | $39.31 | $12,973.62 |
DisclosureSEC source: 0001179110-22-000631 · edgar.xml · nonDerivative · entry 1 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 39,010 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 1,115 shares of restricted stock from a January 22, 2019 grant of 4,620 shares of restricted stock. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:16 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 63,000 | $0.00 Strike: $38.10 | $0.00 |
DisclosureSEC source: 0001179110-22-000394 · edgar.xml · derivative · entry 6 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 63,000 Underlying: Common Stock · 63,000 shares Expires 2032-01-06 F4 · derivative.exercise_date: This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:16 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 165,000 | $0.00 Strike: $38.10 | $0.00 |
DisclosureSEC source: 0001179110-22-000394 · edgar.xml · derivative · entry 5 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 165,000 shares Expires 2032-01-06 F4 · derivative.exercise_date: This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:16 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 16,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-000394 · edgar.xml · nonDerivative · entry 4 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 39,340 F2 · shares: Restricted stock units granted on January 7, 2022 that vest in four equal installments over four years, commencing on January 7, 2023. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:16 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 294 | $38.53 | $11,326.35 |
DisclosureSEC source: 0001179110-22-000394 · edgar.xml · nonDerivative · entry 3 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 22,540 F3 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 990 RSUs from a January 6, 2021 grant of 3,960 RSUs. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:16 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 44,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-000394 · edgar.xml · nonDerivative · entry 2 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,446 F2 · shares: Restricted stock units granted on January 7, 2022 that vest in four equal installments over four years, commencing on January 7, 2023. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:16 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,869 | $38.53 | $72,003.23 |
DisclosureSEC source: 0001179110-22-000394 · edgar.xml · nonDerivative · entry 1 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,446 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 6,900 RSUs from a January 6, 2021 grant of 27,600 RSUs. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 21:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 378 | $41.16 | $15,559.24 |
DisclosureSEC source: 0001179110-22-000299 · edgar.xml · nonDerivative · entry 1 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 22,834 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 1,313 shares of restricted stock from a January 3, 2018 grant of 5,250 shares of restricted stock. F2 · balance_after: Includes 206 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending June 30, 2021 and 285 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending December 31, 2021. Read SEC document |
| June 11, 2021 Filed Jun 11, 2021 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 36,400 | $0.00 Strike: $42.95 | $0.00 |
DisclosureSEC source: 0001179110-21-006621 · edgar.xml · derivative · entry 2 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 36,400 Underlying: Common Stock · 36,400 shares Expires 2031-06-10 F2 · derivative.exercise_date: This option was granted on June 11, 2021, and vests over four years, with 25% of the shares underlying the option vesting on June 11, 2022, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on September 11, 2022. Read SEC document |
| June 11, 2021 Filed Jun 11, 2021 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 6,240 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-006621 · edgar.xml · nonDerivative · entry 1 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 22,721 F1 · shares: Restricted stock units granted on June 11, 2021 that vest in four equal installments over four years, commencing on June 11, 2022. Read SEC document |
| April 13, 2021 Filed Apr 16, 2021 00:16 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 1,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-004459 · edgar.xml · nonDerivative · entry 1 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 16,481 F1 · shares: Restricted stock units granted on April 13, 2021 that vest in four equal installments over four years, commencing on April 13, 2022. Read SEC document |
| February 01, 2021 Filed Feb 2, 2021 23:19 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 283 | $56.96 | $16,118.55 |
DisclosureSEC source: 0001179110-21-001092 · edgar.xml · nonDerivative · entry 2 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 15,081 F2 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 1,213 RSUs from a January 29, 2020 grant of 4,855 RSUs. Read SEC document |
| February 01, 2021 Filed Feb 2, 2021 23:19 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,968 | $56.96 | $112,089.41 |
DisclosureSEC source: 0001179110-21-001092 · edgar.xml · nonDerivative · entry 1 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,315 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 8,250 RSUs from a January 29, 2020 grant of 33,000 RSUs. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 21:23 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 350 | $62.05 | $21,718.90 |
DisclosureSEC source: 0001179110-21-000872 · edgar.xml · nonDerivative · entry 1 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 15,364 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 1,115 shares of restricted stock from a January 22, 2019 grant of 4,620 shares of restricted stock. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 22:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 23,100 | $0.00 Strike: $66.49 | $0.00 |
DisclosureSEC source: 0001179110-21-000470 · edgar.xml · derivative · entry 4 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 23,100 Underlying: Common Stock · 23,100 shares Expires 2031-01-05 F2 · derivative.exercise_date: This option was granted on January 6, 2021, and vests over four years, with 25% of the shares underlying the option vesting on January 6, 2022, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 6, 2022. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 22:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 161,000 | $0.00 Strike: $66.49 | $0.00 |
DisclosureSEC source: 0001179110-21-000470 · edgar.xml · derivative · entry 3 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,000 Underlying: Common Stock · 161,000 shares Expires 2031-01-05 F2 · derivative.exercise_date: This option was granted on January 6, 2021, and vests over four years, with 25% of the shares underlying the option vesting on January 6, 2022, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 6, 2022. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 22:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 3,960 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-000470 · edgar.xml · nonDerivative · entry 2 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 15,714 F1 · shares: Restricted stock units granted on January 6, 2021 that vest in four equal installments over four years, commencing on January 6, 2022. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 22:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 27,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-000470 · edgar.xml · nonDerivative · entry 1 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,283 F1 · shares: Restricted stock units granted on January 6, 2021 that vest in four equal installments over four years, commencing on January 6, 2022. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 21:57 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 382 | $62.37 | $23,825.34 |
DisclosureSEC source: 0001179110-21-000413 · edgar.xml · nonDerivative · entry 3 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 11,754 F4 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 1,312 shares of restricted stock from a January 3, 2018 grant of 5,250 shares of restricted stock. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 21:57 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 284 | $62.37 | $17,713.08 |
DisclosureSEC source: 0001179110-21-000413 · edgar.xml · nonDerivative · entry 2 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 12,136 F2 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 975 RSUs from a January 3, 2017 grant of 3,900 RSUs. F3 · balance_after: Includes 242 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending December 31, 2020. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 21:57 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,402 | $62.37 | $87,442.74 |
DisclosureSEC source: 0001179110-21-000413 · edgar.xml · nonDerivative · entry 1 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,683 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 5,400 shares of restricted stock from a January 3, 2017 grant of 21,600 shares of restricted stock. Read SEC document |
| December 30, 2020 Filed Dec 31, 2020 21:06 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 115,937 | $33.02 Strike: $33.02 | $3,828,239.74 |
DisclosureSEC source: 0001179110-20-012343 · edgar.xml · derivative · entry 10 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,063 Underlying: Common Stock · 115,937 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F9 · derivative.exercise_date: This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020. Read SEC document |
| December 30, 2020 Filed Dec 31, 2020 21:06 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 169,781 | $30.86 Strike: $30.86 | $5,239,441.66 |
DisclosureSEC source: 0001179110-20-012343 · edgar.xml · derivative · entry 9 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,219 Underlying: Common Stock · 169,781 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F8 · derivative.exercise_date: Currently exercisable. Read SEC document |
| December 30, 2020 Filed Dec 31, 2020 21:06 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 7,938 | $63.25 | $502,046.75 |
DisclosureSEC source: 0001179110-20-012343 · edgar.xml · nonDerivative · entry 8 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,085 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F7 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $62.93 to $63.55 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 30, 2020 Filed Dec 31, 2020 21:06 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 30,060 | $62.27 | $1,871,776.08 |
DisclosureSEC source: 0001179110-20-012343 · edgar.xml · nonDerivative · entry 7 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,023 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $61.89 to $62.77 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 30, 2020 Filed Dec 31, 2020 21:06 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 77,939 | $61.43 | $4,787,792.77 |
DisclosureSEC source: 0001179110-20-012343 · edgar.xml · nonDerivative · entry 6 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,083 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $60.88 to $61.87 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 30, 2020 Filed Dec 31, 2020 21:06 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 115,937 | $33.02 | $3,828,239.74 |
DisclosureSEC source: 0001179110-20-012343 · edgar.xml · nonDerivative · entry 5 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,022 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. Read SEC document |
| December 30, 2020 Filed Dec 31, 2020 21:06 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 8,212 | $63.19 | $518,924.49 |
DisclosureSEC source: 0001179110-20-012343 · edgar.xml · nonDerivative · entry 4 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,085 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $62.91 to $63.55 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 30, 2020 Filed Dec 31, 2020 21:06 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 38,779 | $62.34 | $2,417,560.42 |
DisclosureSEC source: 0001179110-20-012343 · edgar.xml · nonDerivative · entry 3 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,297 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $61.90 to $62.89 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 30, 2020 Filed Dec 31, 2020 21:06 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 122,790 | $61.43 | $7,543,358.07 |
DisclosureSEC source: 0001179110-20-012343 · edgar.xml · nonDerivative · entry 2 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,076 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $60.90 to $61.89 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 30, 2020 Filed Dec 31, 2020 21:06 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 169,781 | $30.86 | $5,239,441.66 |
DisclosureSEC source: 0001179110-20-012343 · edgar.xml · nonDerivative · entry 1 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,866 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 137,500 | $18.01 Strike: $18.01 | $2,476,375.00 |
DisclosureSEC source: 0001179110-20-011800 · edgar.xml · derivative · entry 26 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 137,500 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F24 · derivative.exercise_date: This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 18,125 | $11.23 Strike: $11.23 | $203,543.75 |
DisclosureSEC source: 0001179110-20-011800 · edgar.xml · derivative · entry 25 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,875 Underlying: Common Stock · 18,125 shares Expires 2027-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F23 · derivative.exercise_date: This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.